Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

ONO-4641 Met Primary Endpoint of Phase II Study in Multiple Sclerosis Patients
Chronic cerebrospinal venous insufficiency: masked multimodal imaging assessment.
UPDATE 2-FDA panel supports approval of Sanofi's MS drug Lemtrada
Safety Study of GNbAC1 in Multiple Sclerosis Patients
Design and screening of a glial cell-specific, cell penetrating Peptide for therapeutic applications in multiple sclerosis.
Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis.
Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia.
Long-term follow-up of vanishing tumors in the brain: How should a lesion mimicking primary CNS lymphoma be managed?
Effects of exercise in experimental autoimmune encephalomyelitis (an animal model of multiple sclerosis).
Long term follow up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.
The effect of Nintendo(R) Wii(R) on balance in people with multiple sclerosis: a pilot randomized control study.
Acorda Therapeutics announces positive AMPYRA® (dalfampridine) Phase 2 data in people with post-stroke deficits
Mechanism for p38α-mediated experimental autoimmune encephalomyelitis.
[Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain. Reply].
Teva Announces Approval of Three-Times-A-Week COPAXONE® 40 mg/mL in Russia for the Treatment of Relapsing-Remitting Multiple Sclerosis
Acute liver failure and liver transplantation in a patient with multiple sclerosis treated with interferon beta.
Normal outcome of pregnancy with ongoing treatment with natalizumab.
Amiloride HCI Tablets, USP 5 mg
Fingolimod Therapy in Early Multiple Sclerosis: An Efficacy Analysis of the TRANSFORMS and FREEDOMS Studies by Time Since First Symptom.
Sanofi sees US FDA ruling for MS drug Lemtrada in Q4
Vitamin D and multiple sclerosis: a critical review and recommendations on treatment.
[Diagnosis of multiple sclerosis - the 2010 revision of the McDonald criteria.]
Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
The effects of massage therapy on multiple sclerosis patients' quality of life and leg function.

Pages